FINARO
Finaro , den globale indløser og bank, der er specialister indenfor international handel, har i dag offentliggjort Ruben Frimand Nielsen som Vicepræsident for Salg- og Forretningsudvikling for de Nordiske lande.
Tidligere business manager hos Mastercard, Ruben, vil lede vækststrategien i Danmark, Sverige, Norge, Finland, Færøerne, Island og Grønland, side om side med udvidelsen af det globale Finaro-team. Inden han sluttede sig til Finaro, var Ruben ansvarlig for international porteføljeadministration, salg og produktstrategi, for afdelingen payments international hos Mastercard. Derfor er han klar til at bringe Finaros globale betalingsløsninger ud til virksomheder i en af de hurtigst voksende e-handels regioner i Europa.
Danske, svenske, norske og finske forbrugere brugte tilsammen 46,5 milliarder euro online i 2020, med 19% af de nordiske handlende der foretog online indkøb på tværs af grænserne . I Danmark købte mere end 90% af forbrugerne ind online i 2020, efterfulgt af 87% i Norge og 86% i Sverige . Disse tal forventes at stige i 2022, da forbrugerne har vænnet sig til disse indkøbsmetoder og gør brug af mobil handel såsom lokale digitale wallets og in-app payments.
Achiya Fried, Chief Commercial & Strategy Officer hos Finaro , fortæller: “Jeg er begejstret for, at byde Ruben velkommen. Vi har ambitiøse vækstplaner, og en central del af dette omfatter udvidelser i de Nordiske lande. Rubens betalingserfaring og viden indenfor strategi vil helt sikkert blive en af drivkrafterne for Finaros voksende fremdrift i regionen, og jeg ser frem til, at se hvad han kan gøre for teamet og for virksomheden.”
Igal Rotam, CEO for Finaro , siger: “Vi er begejstrede for, at Ruben slutter sig til vores virksomhed for at støtte denne vækst og udføre den strategiske plan for de Nordiske lande. Hans kompetencer og dybdegående indblik vil sikre, at Finaros kunder på det Nordiske marked har adgang til de innovative og banebrydende betalingsløsninger, som de har behov for, for at kunne betjene deres egne voksende globale kunder.”
Ruben Frimand Nielsen, Vicepræsident for Salg - & Forretningsudvikling hos Finaro, kommenterede om sin nye titel og arbejde : “Det er en utrolig spændende tid at blive en del af Finaro på og være en del af den stærke vækst og ambitiøse planer for fremtiden. Den varme velkomst, og mit eksisterende kendskab til virksomheden samt produkterne har givet mig en smidig overgang - og jeg ser frem til, at påtage mig rollen for væksten samt at sætte et fodaftryk på det Nordiske marked. Jeg ser frem til at komme i gang.’’
Rubens udnævnelse kommer efter det nylige skift af Finaros navn fra Credorax, der afspejler dens nye identitet og forpligtelse til at realisere dens vision for betalinger, hvor handel er uden landegrænser og fri for teknologiske, fysiske og geografiske begrænsninger. Efter et utroligt succesfuldt år i 2021, med mere end 10 milliarder US dollars i samlet behandlet volume for mere end 5.000 handelsdrivende, er Finaro dedikeret til at gøre komplekse betalinger enkle, kombineret med dens instinktive passion for kundeservice, som går langt videre end det normale.
Om Finaro
Finaro er en global betalingsudbyder der på tværs af landegrænser styrker den internationale handel gennem enkle betalinger og innovativ teknologi. Vores dedikerede team, enestående teknologiske formåen, produktinnovation og kundefokuserede tilgang, gør os i stand til at forenkle kompleksitet og skabe samlet købsoplevelse der medfører vækst og giver ro i sindet for vores kunder. For at lære mere kan du besøge www.finaro.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220322005960/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
